<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81747">
  <stage>Registered</stage>
  <submitdate>28/07/2004</submitdate>
  <approvaldate>28/07/2004</approvaldate>
  <actrnumber>ACTRN12607000064404</actrnumber>
  <trial_identification>
    <studytitle>A phase III international randomized trial of single versus multiple fractions for re-irradiation of painful bone metastases</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 03.08 - A phase III international randomized trial of single versus multiple fractions for re-irradiation of painful bone metastases from any cancer to increase pain relief</scientifictitle>
    <utrn />
    <trialacronym>TROG 03.08</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR579</secondaryid>
    <secondaryid>Clinicaltrials.gov: NCT00080912</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Painful bone metastates from any cancer after previous palliative radiotherapy.</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 2: Multiple fractionation (20 Gy, 5 fractions - 4Gy x 5 daily fractions, eight fractions (for spine and/or whole pelvis only))</interventions>
    <comparator>Arm 1: Single fractionation (8Gy, one fraction)</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rates</outcome>
      <timepoint>At 2 months from the start of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Incidence of acute radiation related side effects</outcome>
      <timepoint>Day 7 and 14 from the first fraction of radiation. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Freedom from progression</outcome>
      <timepoint>Measured at each follow up visit until progression. Follow up for every month for 6 months starting one month from the first day re-irrradiation, then at months 9 and 12.  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. European Organisation for Research and Treatment for Cancer Qulaity of life questionnaire (EORTC QLQ-C30).</outcome>
      <timepoint>Months 1, 2, 3, 4, 5 and 6 after radiation.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patient must have histologically or cytologically proven malignancy.  Histological diagnosis may be established from needle biopsy, bone marrow biopsy, cytology, or a surgical biopsy or resection.  All malignant histologies/cytologies are eligible. 2. Plain radigraphs, radionuclide bone scans, CT scans and/or magnetic resonance imaging confirm the presence of bone metastatses corresponding to clinically painful area.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Clinical or radiological evidence of spinal cord compression at the time of assessment for this study.2. Clinical or radiological evidence of pathological fractures of extremities in the area to be re-irradiated.3. The treatment area has received prior palliative surgery.4. There is planned surgical intervention on the treated bone.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone</concealment>
    <sequence>Computer generated</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>3/09/2004</anticipatedstartdate>
    <actualstartdate>2/03/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate>28/05/2012</actualenddate>
    <samplesize>850</samplesize>
    <actualsamplesize>850</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Westmead Private Hospital - Westmead</hospital>
    <hospital>Mater Adult Hospital - South Brisbane</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Peter MacCallum Cancer Institute - East Melbourne</hospital>
    <hospital>Wesley Hospital Kogarah - Kogarah</hospital>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Royal Brisbane &amp; Womens Hospital - Herston</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>National Cancer Insitute of Canada</primarysponsorname>
    <primarysponsoraddress>10 Alcorn Avenue, Suite 200
Toronto, Ontario  M4V 3B1</primarysponsoraddress>
    <primarysponsorcountry>Canada</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council Project Grant</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Multistate cancer council grant</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Mayne Pharma</fundingname>
      <fundingaddress>Mayne Pharma
55 New Oxford Street
London
WC1A 1BS</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Trans Tasman Radiation Oncology Group (TROG)</sponsorname>
      <sponsoraddress>Edith St Waratah NSW 2298</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Radiation Therapy Oncology Group
</othercollaboratorname>
      <othercollaboratoraddress>RTOG Headquarters
1818 Market Street, Suite 1600
Philadelphia, PA 19103</othercollaboratoraddress>
      <othercollaboratorcountry>United States of America</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Cancer Research UK
</othercollaboratorname>
      <othercollaboratoraddress>Angel Building, 407 St John Street, London EC1V 4AD</othercollaboratoraddress>
      <othercollaboratorcountry>United Kingdom</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Assistance Publique - Hopitaux de Paris</othercollaboratorname>
      <othercollaboratoraddress>3 Victoria Avenue 75004 Paris
</othercollaboratoraddress>
      <othercollaboratorcountry>France</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Radiotherapy is an effective treatment for people with cancer that has spread to their bones and is causing problems. Sometimes, a second course of radiation is required. This international randomised trial will determine if it is better for a second course of radiation to be done as one large treatment, or as several smaller treatments.</summary>
    <trialwebsite />
    <publication>Chow E, Hoskin P, Wuz J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A Phase III International Randomised Trial Comparing Single with Multiple Fractions for Re-irradiation of Painful Bone Metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. J Clin Oncol. 2006; 18 (2):125-128. (Editorial)  

 Roos D. Response to Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian centers. Int J Rad Onc Biol Phys. 2010; 78 (2): 637-637. 

 Chow E, van der Linden Y, Roos DE, Hartsell WF, Hoskin P, Wu Jackson S, Brundage M, Nabid A, Tissing-Tan C, Oei B, Babington S, Demas W, Wilson F, Meyer R, Chen B, Wong R.  Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.  Lancet Oncol, 2014 Feb15; (2):164-171.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater QRI</ethicname>
      <ethicaddress />
      <ethicapprovaldate>11/11/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>MacArthur Cancer Therapy Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>W.P Holman Clinic</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wesley Radiation Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Daniel Roos</name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax>+61 8 8222 2016</fax>
      <email>droos@mail.rah.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Daniel Roos</name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax>+61 8 8222 2016</fax>
      <email>droos@mail.rah.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>Department of Radiation Oncology Locked Bag 7 Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 4014 3910  </phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>EDWARD CHOW</name>
      <address>Department of Radiation Oncology,
Odette Cancer Centre,
Sunnybrook Health Sciences Centre,
2075 Bayview Avenue,
Toronto, ON  
M4N 3M5
</address>
      <phone>+1 416 480-4998</phone>
      <fax />
      <email>edward.chow@sunnybrook.ca</email>
      <country>Canada</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>